SCHEMBL6990776

SCHEMBL6990776

CC(C)(C)OC(=O)N1CCC[C@H]1Cc1cc(Cl)cc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 2/20 0.48
ALDH1A1 P00352 1/20 0.48
FABP4 P15090 1/20 0.45
LMNA P02545 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
OPRK1 P41145 2/20 0.43
APP P05067 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
DRD2 P14416 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
SLC6A2 P23975 1/20 0.43
HRH2 P25021 1/20 0.43
HTR1D P28221 1/20 0.43
HTR1B P28222 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR7 P34969 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132449 0.92 OPRK1 (0.46) STSALDH1A1FABP4LMNANPSR1
SCHEMBL10132370 0.88 ALDH1A1 (0.50) STSALDH1A1LMNANPSR1MEN1
SCHEMBL10132293 0.88 ALDH1A1 (0.51) STSALDH1A1LMNANPSR1OPRK1
SCHEMBL10132508 0.84 OPRK1 (0.56) ALDH1A1OPRK1SLC6A3TMEM97SIGMAR1
SCHEMBL22036268 0.84 HPGD (0.49) STSALDH1A1OPRK1APPHTR1A
SCHEMBL10132402 0.84 ALDH1A1 (0.48) ALDH1A1LMNANPSR1OPRK1APP
SCHEMBL10132428 0.83 LMNA (0.51) ALDH1A1LMNANPSR1OPRK1MEN1
SCHEMBL698218 0.82 NR1H2 (0.54) STSMEN1KMT2ANR1H2NR1H3
SCHEMBL698422 0.82 NR1H2 (0.54) STSMEN1KMT2ANR1H2NR1H3
SCHEMBL27854990 0.82 NR1H2 (0.54) STSMEN1KMT2ANR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889683-B2 Substituted quinoxalines as inhibitors of fatty acid binding protein MERCK SHARP & DOHME CORP. (US) 2014-11-18 US disclosed
US-8889683-B2 Substituted quinoxalines as inhibitors of fatty acid binding protein MERCK SHARP & DOHME CORP. (US) 2014-11-18 US disclosed
US-20120122837-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN MERCK SHARP & DOHME LLC 2012-05-17 US disclosed
US-20120122837-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN MERCK SHARP & DOHME LLC 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122837-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN FABP4, FABP1, FABP3 STS 4531/4885ALDH1A1 1295/4885FABP4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.